Finkelstein Thompson LLP Announces Investigation of Micromet, Inc.

Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Micromet, Inc. (“Micromet” or “the Company”) (NasdaqGS: MITI), concerning the proposed acquisition of the Company by Amgen, Inc. (NasdaqGS: AMGN). Under the terms of the transaction, Micromet shareholders would receive $11.00 per share in cash, in a deal worth approximately $1.16 billion.

In recent months Micromet has announced positive clinical trial results and a possible expedited approval process for its cancer drug blinatumobab. The Company's share price has more than doubled recently, rising from $4.37 in September 2011 to $8.88 in January 2012. Indeed, at least one analyst has set a target price of $12.00 for the Company's stock.

The investigation is focused on the potential unfairness of the consideration to Micromet's shareholders, the process by which the Company's Board of Directors considered the transaction, and potential conflicts of interests among Micromet's Board members.

If you are interested in discussing your rights as a Micromet shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com.

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our website at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.